DRUG
Linaclotide 290 micrograms
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Status
Completed
Phase
Phase 3
Enrollment
633
Locations
108
Results
Posted
Publications
2
Study summary
The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder
Interventions
DRUG
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
DRUG
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
DRUG
Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Timeline
First posted
Oct 3, 2008
Study start
Sep 2008
Primary completion
Jul 2009
Study completion
Aug 2009
Results posted
Jan 30, 2013
Registry updated
Jan 30, 2013
Outcomes
Complete Spontaneous Bowel Movement (CSBM) Overall Responder
Time frame · Change from Baseline to Week 12
A 12-week CSBM overall responders was defined as a patient who for at least 9 of the 12 weeks of the treatment period had a CSBM weekly frequency rate that was 3 or greater and increased by 1 or more from baseline. A CSBM was defined as a spontaneous bowel movement (SBM) that was associated with a sense of complete evacuation. An SBM was defined as a bowel movement (BM) that occurred in the absence of laxative, enema, or suppository use on either the calendar day of the BM or the calendar day before the BM.
12-week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate
Time frame · Change from Baseline to Week 12
The number of CSBMs per week.
12-Week Spontaneous Bowel Movement (SBM) Frequency Rate
Time frame · Change from Baseline to Week 12
A patient's 12-week spontaneous bowel movement (SBM) frequency rate was the number of SBMs per week calculated over the 12-weeks of the treatment period.
12-Week Stool Consistency
Time frame · Change from Baseline to Week 12
The consistency of each BM was assessed using the 7-point Bristol Stool Form Scale: 1. = separate hard lumps like nuts \[difficult to pass\] 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges \[passed easily\] 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces \[entirely liquid\]
12-Week Severity of Straining
Time frame · Change from Baseline to Week 12
Straining is measured on a 5-point scale, where a value of 1 is "not at all" and a value of 5 is "an extreme amount.
12-Week Abdominal Discomfort
Time frame · Change from Baseline to Week 12
Abdominal discomfort is based on a 5-point scale where a value of l is "none" and a value of 5 is "very severe."
12-Week Bloating
Time frame · Change from Baseline to Week 12
Bloating was based on a 5-point scale where a value of l is "none" and a value of 5 is "very severe".
12-Week Constipation Severity
Time frame · Change from Baseline to Week 12
Constipation severity was based on a 5-point ordinal scale where a value of l is "none" and a value of 5 is "very severe".
Eligibility
Inclusion Criteria: * Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings * Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests * Patient meets protocol criteria for CC: reports \< 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs * Patient demonstrates continued chronic constipation through Pretreatment Period * Patient is compliant with IVRS Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS) * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
Study locations
Canada · United States. Showing up to 24 locations stored in the fast local snapshot.
Forest Investigative Site
Birmingham, Alabama, United States
Forest Investigative Site
Birmingham, Alabama, United States
Forest Investigative Site
Huntsville, Alabama, United States
Forest Investigative Site
Chandler, Arizona, United States
Forest Investigative Site
Mesa, Arizona, United States
Forest Investigative Site
Peoria, Arizona, United States
Forest Investigative Site
Phoenix, Arizona, United States
Forest Investigative Site
Scottsdale, Arizona, United States
Forest Investigative Site
Tucson, Arizona, United States
Forest Investigative Site
Burbank, California, United States
Forest Investigative Site
Encinitas, California, United States
Forest Investigative Site
Foothill Ranch, California, United States
Forest Investigative Site
Los Angeles, California, United States
Forest Investigative Site
Orange, California, United States
Forest Investigative Site
Westlake Village, California, United States
Forest Investigative Site
Boulder, Colorado, United States
Forest Investigative Site
Colorado Springs, Colorado, United States
Forest Investigative Sites
Denver, Colorado, United States
Forest Investigative Site
Longmont, Colorado, United States
Forest Investigative Site
Wheat Ridge, Colorado, United States
Forest Investigative Site
Waterbury, Connecticut, United States
Forest Investigative Site
Boca Raton, Florida, United States
Forest Investigative Site
Bradenton, Florida, United States
Forest Investigative Site
Brooksville, Florida, United States
Publications
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.